Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity. - Wikidata - awgldk - TriplyDB

Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity.

Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity.

http://www.wikidata.org/entity/Q37434670

about

Natural Killer Cells for Therapy of Leukemia Immune Cells in Cancer Therapy and Drug Delivery Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells Natural Killer Cells for Immunotherapy - Advantages of the NK-92 Cell Line over Blood NK Cells The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer Selection and expansion of natural killer cells for NK cell-based immunotherapy Trial Watch: Adoptive cell transfer for oncological indications T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect Trial watch: Dendritic cell-based anticancer therapy Manufacturing Natural Killer Cells as Medicinal Products Immunological and Translational Aspects of NK Cell-Based Antitumor Immunotherapies Advantages and applications of CAR-expressing natural killer cells Utilizing chimeric antigen receptors to direct natural killer cell activity Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity Natural killer cells for cancer immunotherapy: pluripotent stem cells-derived NK cells as an immunotherapeutic perspective Classification of current anticancer immunotherapies Genetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications.In Vitro and In Vivo Comparison of Lymphocytes Transduced with a Human CD16 or with a Chimeric Antigen Receptor Reveals Potential Off-Target Interactions due to the IgG2 CH2-CH3 CAR-Spacer Models to Study NK Cell Biology and Possible Clinical Application.A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer.An allogeneic NK cell line engineered to express chimeric antigen receptors: A novel strategy of cellular immunotherapy against cancer.An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele.Role of Natural Killer Cells in HIV-Associated Malignancies.Lentiviral vectors in cancer immunotherapy.Critical roles of co-activation receptor DNAX accessory molecule-1 in natural killer cell immunity.NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy.Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy.The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments.Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV.Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor.Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies.In Vitro Generation of Human NK Cells Expressing Chimeric Antigen Receptor Through Differentiation of Gene-Modified Hematopoietic Stem Cells.CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies.Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma.CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies.ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.Adoptive Cellular Therapy (ACT) for Cancer Treatment.Immunosenescence: limitations of natural killer cell-based cancer immunotherapy.Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells.Modeling Natural Killer Cell Targeted Immunotherapies.

P2860

Q26745906-70E68385-C922-4B54-AF6D-CFD8D152CE27 Q26747061-8D439A69-7C61-4DF1-8AB4-23D7FECF484A Q26751011-97C55DED-A7FD-450B-A31A-EC6550C55C05 Q26751020-23746849-FD16-4C84-8562-7CAC19CF5572 Q26774678-AF4290A6-F79F-4A65-B276-1E1FA5FCEAAC Q26774777-3662CC49-8D02-4526-B4A1-27A49DE1D3A7 Q26785545-6B37AEF0-DE3B-47AC-B7E3-50BEC561E07F Q26826830-2BEC5FA3-0B60-47B5-A7AB-A5AD2EEF45BB Q27024047-3537A857-2792-46E4-B4B8-1EA1729689DF Q28069992-18A71D05-8C4E-493B-9C43-508591D80AD8 Q28079180-973CA573-FF45-4FB1-94FB-2A09BCADCEAD Q28080875-CA63C614-0D87-4B56-914B-4957DA84E7D6 Q28082868-8E547B7C-578C-44A5-B668-37DE1F3677B6 Q33700795-D34C4314-94E4-4CBC-9233-36F66F517951 Q34180695-7313D0B2-507B-423C-913F-5A90ACC51EE3 Q35149637-8F724037-CD93-41CC-B98E-12E5D7E315C9 Q35711209-A911D93B-525F-4CFB-BCE4-BF5705CDACA8 Q36333154-F482D7BD-3397-411B-A98F-1DF90C44AC62 Q36635914-8AB38038-35F3-48AB-9985-5B71103F6E17 Q37376346-0224F6C8-6224-4BD6-B903-E4B8A0E70B58 Q37488222-CB474FE5-BDE3-416F-AF25-5B9605684788 Q37686302-06BE854A-980F-4658-B837-C9610FE62964 Q37712593-D35C9167-AF2F-45CB-A245-23672F157E5E Q38389312-C3B37072-45CD-4635-B2F1-5BA214194764 Q38559350-C45F70E8-77F1-41BE-91B3-6990F12402E5 Q38631020-02A26D57-8948-4130-AA09-275C78FCC461 Q38666579-D28BAF83-362F-4FDB-A9CE-121140FC2077 Q38670431-79ECE03D-50A8-40F4-9B60-71310A857BD7 Q38685785-6C44D9B2-D09B-4C4C-BA0D-DA345E352097 Q38722015-407AC8BE-673C-40DB-854C-95634EA75416 Q38753649-9EC53AB6-7E0C-4E91-AAC7-F78F32B84214 Q38771094-F7C920A6-00E2-456B-AD69-42066257B476 Q38783833-7CF1B1C0-2721-469F-8931-9622795A2699 Q38803361-9B43C1BE-9291-48A7-962F-DEE643439D03 Q38807514-355AD896-7CA5-4F72-94C5-BDBA7648ADB2 Q38814097-D1587573-49ED-40DF-9451-44590E735C11 Q38848219-8686F18A-AB59-41EC-BCA4-B6B089BB7553 Q38928938-DE727584-0252-49F9-BE86-1858EE828E5B Q39110347-2698D27D-E5EF-4ACD-967C-0915A1D17226 Q39239278-2FF9B7A1-B7FC-4673-B05B-3E18D39ADD3F

P2860

Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity.

http://www.wikidata.org/entity/Q37434670

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 22 October 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Retargeting NK-92 cells by mea ...... pendent cellular cytotoxicity.

@en

Retargeting NK-92 cells by mea ...... pendent cellular cytotoxicity.

@nl

type

label

Retargeting NK-92 cells by mea ...... pendent cellular cytotoxicity.

@en

Retargeting NK-92 cells by mea ...... pendent cellular cytotoxicity.

@nl

prefLabel

Retargeting NK-92 cells by mea ...... pendent cellular cytotoxicity.

@en

Retargeting NK-92 cells by mea ...... pendent cellular cytotoxicity.

@nl

P1433

Q37434670-5FBF4F0C-F187-4FCB-9C6C-DA33752CFF42

P1476

Q37434670-C33B4009-B559-4E76-A962-71EE00D3DFE1

P2093

Q37434670-04AC4081-38D0-40B1-9654-FF4A1ED1F2D5

Q37434670-8D79A065-7177-47EA-AE31-52E01AC9CF61

Q37434670-97DFFFD6-3373-4E5D-BB72-B2D6E2FD726A

Q37434670-9813060D-E963-4C32-92CE-7C22B4D7A7F3

Q37434670-A19C3D75-9E07-4746-BB1D-15F79D16BD34

Q37434670-E88932D7-9443-4539-A1F2-BACE4D2C1AEB

Q37434670-F748D5EA-D33F-4EB0-9794-75547136BA48

P2860

Q37434670-008A6701-654F-435D-A365-6EE546CA362B

Q37434670-03DF6CEC-B2B2-4B65-B0FC-E0CD930635D0

Q37434670-0CB166DE-5F26-4059-920D-5423AF3DB229

Q37434670-1C089E49-8947-490B-BFA1-9184D3485F22

Q37434670-29065000-3185-4CE6-8CBA-2E425E7F7060

Q37434670-2A1A2209-1179-4176-B9CE-1521C9A1C064

Q37434670-2BAF37D3-BEFB-465A-884F-CAFF5BA6DA9D

Q37434670-41E07015-4754-4810-87EC-33BE515DDF0D

Q37434670-425DD212-8530-4030-AE2D-1519AE8B488A

Q37434670-587E0ACD-13B5-4297-89A0-7BAE2EF1D6D6

P304

Q37434670-4A722EC6-38E4-43D3-A82B-E02848925750

P31

Q37434670-FF99F434-F925-49FB-9196-8B841D9BAC1F

P356

Q37434670-0352B47B-3304-4D87-8F95-2D4767266C97

P433

Q37434670-9F2BDB45-51AB-4943-A712-0A85B98044DA

P478

Q37434670-4059E606-7B99-4FF8-92CE-F91C97405B22

P577

Q37434670-C4C66F86-FD8D-4FE3-BCFE-F84D47F4A23F

P5875

Q37434670-731D2D0B-3C14-4891-82FF-0FD1624C530F

P698

Q37434670-74570A1A-1D65-4ED5-9ABD-113952B6EA23

P921

Q37434670-494F32C5-DCD7-4C51-8B40-B5F26985B392

Q37434670-DD8B66F8-1659-496A-A83E-3320381447E2

P932

Q37434670-F6CA0DD1-6484-4FB7-BA37-15A6254FFBA7

P356

P1433

P1476

Retargeting NK-92 cells by mea ...... pendent cellular cytotoxicity.

@en

P2093

Daniela S Krause

http://www.w3.org/2001/XMLSchema#string

Hans Klingemann

http://www.w3.org/2001/XMLSchema#string

Laurent Boissel

http://www.w3.org/2001/XMLSchema#string

Monica Betancur-Boissel

http://www.w3.org/2001/XMLSchema#string

Richard A Van Etten

http://www.w3.org/2001/XMLSchema#string

Weiquan Lu

http://www.w3.org/2001/XMLSchema#string

Winfried S Wels

http://www.w3.org/2001/XMLSchema#string

P2860

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

Cellular Immunotherapy of Malignancies Using the Clonal Natural Killer Cell Line NK-92

Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy.

Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR).

Donor lymphocyte infusions.

Variant genotypes of the low-affinity Fcgamma receptors in two control populations and a review of low-affinity Fcgamma receptor polymorphisms in control and disease populations.

Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor.

Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia.

Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity.

P304

e26527

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/ONCI.26527

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2013-10-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259632132

http://www.w3.org/2001/XMLSchema#string

P698

24404423

http://www.w3.org/2001/XMLSchema#string

P921

P932

3881109

http://www.w3.org/2001/XMLSchema#string